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Available online 1 April 2014Abstract Despite advances in the field of somatic cell reprogramming, an understanding and exploration of the underlying
mechanisms governing this process are only recently emerging. It is now increasingly apparent that key sequential events
correlate with the reprogramming process; a process previously thought to be random and unpredictable is now looking, to a
greater extent, defined and controlled. Herein, we will review the key cellular and molecular events associated with the
reprogramming process, giving an integrative and conciliatory view of the different studies addressing the mechanism of
nuclear reprogramming.
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Since the discovery that somatic cells could be reprogrammed
to induced pluripotent stem cells (iPSCs) (Takahashi andis an open access article under the CC BY-NC-ND license
755Phases of reprogrammingYamanaka, 2006), many different pathways have been
created based on Waddington's adaptation of the “epigenetic
landscape”, the model used to illustrate cell differentiation
during development (Waddington, 1954). The somatic cell
reprogramming and the process of transdifferentiation,
further expanded the boundaries of cell plasticity giving
rise, for example, to a non-hierarchical model of cell fate
transition, represented by an “epigenetic disk” in which the
ball of cell fate could assume any cell fate, provided that the
master transcription factors were sufficiently expressed
(Ladewig et al., 2013). While there is little doubt that such
cell fate conversions are reproducible, a major hurdle that
precludes further study of the reprogramming process is their
low efficiency (Ho et al., 2011; Stadtfeld and Hochedlinger,
2010). To overcome this, secondary systems were imple-
mented, and the resultant transgenic fibroblast could be
reprogrammed through inducible expression of Oct4, Klf4,
Myc and Sox2 (OKMS) (Carey et al., 2010; Maherali et al.,
2008; Nagy, 2013; Stadtfeld et al., 2010; Woltjen et al.,
2009). These improved reprogramming systems usually utilize
doxycycline-inducible reprogramming factors. This allows
temporally-controlled induction of expression of the re-
programming factors as well as a higher degree of homoge-
neity. As will be discussed during this review, the majority of
the studies addressing the mechanism of reprogramming have
made use of a secondary system.
First milestone: iPS cells are equivalent to ESC
and can be obtained from the reprogramming
of any adult cell
The first and more important questions that needed to be
addressed were whether iPSCs were in fact identical to ESCs,
and whether all cells were amenable to reprogramming. It
was evident that iPSCs were not only morphologically
and functionally equivalent to ESCs, but were also similar
both transcriptionally and epigenetically (Maherali et al.,
2007; Mikkelsen et al., 2008; Okita et al., 2007; Takahashi et
al., 2007; Wernig et al., 2007). While some studies found
differences between ESCs and iPSCs, others that investigat-
ed a broader array of samples showed that the heterogeneity
between ESC and iPSC lines was mainly due to the method
used to derive them (Yamanaka, 2012).
Subsequently, the “reprogramming technology” needed
to prove that iPSCs were the result of reprogrammed cells,
and not the selection of novel uncharacterized tissue-
specific pluripotent cells. This was achieved by reprogramming
cells with specific traceable genetic characteristics, such as
the albumin promoter in hepatocytes, insulin promoter in
pancreatic beta cells or the recombined immunoglobulin locus
of B lymphocytes (Aoi et al., 2008; Hanna et al., 2008;
Stadtfeld et al., 2008a). Indeed, Hanna and colleagues
demonstrated that iPSCs could emerge from daughter cells
from any given cell of a starting population, provided that the
cells were still viable and the four reprogramming factors
could maintain expression for extended periods (Hanna et al.,
2009).
The finding that the timing of faithful reprogramming
varies widely among cells, suggests that at least one
event driving the reprogramming process is likely to be
stochastic. A priori the steps leading to successfulreprogramming may involve one or several stochastic events
and could be divided by: a) the nature of the molecular
events taking place during this process, which raises the
question of whether reprogramming can be achieved
through different molecular pathways (Fig. 1A) and b) the
order of these key events: is there a hierarchy or can they
be acquired independently? (Fig. 1B). Finally, if these events
transpire in an orderly fashion we will be able to unveil
them. If on the contrary, these events were acquired
“accidently” in nature and timing, their time of occurrence
will remain largely unknown and highly susceptible to
variability (Fig. 1C).
In the subsequent sections we attempt to consolidate
and discuss recent findings that have emerged from the
study of the reprogramming process. Primarily, this is
composed of three phases: initiation, maturation and
stabilization and are discussed in greater detail below
(Fig. 2).
Second milestone: unveiling the
reprogramming pathway
Early events — initiation phase — first wave
Different molecular transitions during reprogramming
were first documented by the laboratories of R. Jaenisch
and K. Hochedlinger in 2008, when they described distinct
molecular events occurring at defined times during the
reprogramming process (Brambrink et al., 2008; Stadtfeld
et al., 2008b). These events ranged from downregulation
of fibroblast-specific surface markers and the concomitant
upregulation of genes associated with the pluripotency
network, as well as reactivation of telomerase activity.
Based on an extensive transcriptomic profiling time course
during reprogramming of fibroblasts in bulk cultures, the
reprogramming process was subsequently grouped in to three
phases by the laboratory of J. Wrana: the initiation phase,
maturation phase and stabilization phase (Samavarchi-Tehrani
et al., 2010). This early period also correlated with changes in
morphology, such that fibroblast cells (the main somatic
cell model used for reprogramming studies) undergo a
mesenchymal-to-epithelial transition (MET). Molecularly, this
is characterized by a loss of the somatic cell signature, for
example the loss of the transcription factors Snai1/2 or
Zeb1/2, which was also described in previous studies
(Mikkelsen et al., 2008; Sridharan et al., 2009; Stadtfeld
et al., 2008b), and the gain of an epithelial signature, such
as the expression of Cdh1, Epcam or epithelial-associated
miRNA-200 family (Li et al., 2010; Samavarchi-Tehrani et al.,
2010). The importance of these cellular changes was further
highlighted by the demonstration that the cell shape itself can
trigger epigenetic modifications regulating reprogramming
(Downing et al., 2013). In this study, MEFs seeded on
microgrooved surfaces for 3 days that entered a MET, therefore
enhancing the reprogramming efficiency (Downing et al.,
2013). Accordingly, in a kinase shRNA screen attempting to lift
barriers of mouse reprogramming, top hits were 2 kinases
blocking cytoskeletal rearrangement: TESK1 and LIMK2
(Sakurai et al., 2014). Interestingly, TESK1 siRNA led to
enhanced reprogramming in human fibroblasts as well
(Sakurai et al., 2014). Aside from MET-associated changes,
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757Phases of reprogrammingIn order to shed light on the cellular events occurring
during reprogramming, several groups usedmultiple surface
and genomic markers to monitor the progression of cells as
they transit through the reprogramming process. These
studies revealed that during the initiation phase, markers
such as Thy1 and CD44 are lost, while the pluripotency
markers alkaline phosphatase or SSEA1 are gained (Fig. 2)
(Brambrink et al., 2008; Hansson et al., 2012; Mikkelsen
et al., 2008; O'Malley et al., 2013; Polo et al., 2012;
Samavarchi-Tehrani et al., 2010; Stadtfeld et al., 2008b).
Polo and collaborators were able to confirm and expand
the initial work of the Wrana lab by further unveiling the
two waves of molecular changes that transpire during
reprogramming (Polo et al., 2012). A first wave, which
occurs almost in every cell in culture and coincides with the
initiation phase described by Wrana lab, is followed by
gradual molecular changes, until a second wave emerges at
the end of the process. The initiation phase was defined as
the commencement of the reprogramming process until the
first pluripotency-associated genes were expressed, where-
as the first wave encompasses only the high transcriptional
turnover section during the initiation phase. Events taking
place during the initiation phase were validated at the
single cell level by time lapse microscopy, backtracking
faithful events that would lead to a Nanog- or Oct4-
expressing colony: every cell was found to go through an
increase in proliferation and a MET (Araki et al., 2010;
Megyola et al., 2013; Smith et al., 2010).
The initiation phase of reprogramming has beenmost widely
documented to date. While technical reasons may account for
this, the success of those studies resided in the fact that the
vast majority of cells were able to initiate reprogramming (Polo
et al., 2012). Interestingly, the majority of the cells then
became refractory to reprogramming, with few cells subse-
quently proceeding to the next steps of reprogramming.
A possible explanation could be the “innate immunity”
triggering protein degradation, which might explain why even
in secondary systems not all cells reprogram, but can be rescued
by additional overexpression of Yamanaka factors (Buckley et
al., 2012; Polo et al., 2012).
The observed changes in gene and protein expression
correlate with a hierarchical sequence of events that reflect
a deeper interaction between OKSM, co-factors and the
chromatin, which together will ultimately dictate the epige-
netic state. For example, for a gene to be re-expressed, the
region of chromatin needs to be de-condensed, inactive
histone markers need to be removed, the DNA needs to be
demethylated and active histone markers have to be added
(Pasque et al., 2011). All or several of these events have to
happen at each gene that needs to be re-expressed, while at
the same time, the opposite phenomenon has to happen at
lineage-specific genes in order to be repressed. How these
epigenetic events impact on the kinetics of gene transcription
during reprogramming is still poorly understood. Nevertheless,
a few studies have shed some light into how those changes
are orchestrated. Focusing on the initial days of human
reprogramming and therefore underscoring the events
occurring in the initiation phase or first wave, Soufi and
collaborators suggested that high levels of reprogramming
factors cause OKS to bind to many more genes than they would
do physiologically (Soufi et al., 2012). Moreover, recent
studies redefined Myc function as a transcriptional responseamplifier, mostly binding core promoters rather than distant
enhancers (Lin et al., 2012; Nie et al., 2012). This is in
accordance with a previous mouse study showing that Myc
served a different function during reprogramming than OKS
(Sridharan et al., 2009). These findings showed that during the
early stages of reprogramming, Myc binds to accessible DNA
regions, while OKS can bind inactive DNA regions (Soufi et al.,
2012). In addition, these studies suggested that Myc is
responsible for the loss of somatic cell identity of MEFs
and the induction of MET, while OKS mostly acts as pioneer
(Soufi et al., 2012; Sridharan et al., 2009). At the chromatin
level, in MEFs, this phase is characterized by changes
in histone modifications and not DNA methylation (Polo et
al., 2012). Even though, gain and loss of active and repressive
markers happen during the first wave, it seems to be biased to
genes with active chromatin markers (Koche et al., 2011).
Furthermore, a small scale shRNA screen performed during
reprogramming of human fibroblasts showed that the histone
methyltransferase DOT1L had an inhibitory effect on re-
programming and a block in KLF4 induction of MET (Onder
et al., 2012). Finally, the importance of epigenetic
regulators during the initiation phase has been recently
underscored by a paper showing that Tet1, 2, 3 triple
knock-out failed to initiate reprogramming, specifically
because Tets are required to activate the miR-200 family,
which in turn is necessary for MET to occur (Hu et al.,
2014). More information regarding epigenetic regulation
of pluripotency and reprogramming can be found in
recent reviews (Apostolou and Hochedlinger, 2013;
Buganim et al., 2013; Liang and Zhang, 2013; Papp and
Plath, 2013).
In conclusion, every cell undergoing reprogramming will
transit through the initiation phase (Polo et al., 2012). This
may reflect an overall non-stochastic phase. However,
the clear sequence of events driving the initiation phase
has not been completely defined yet. Moreover single cell
analysis during this early phase suggested that the overall
noise in the signature may reflect a stochastic process in
which the path taken does not matter, as long as all the
initiation phase-associated modifications are acquired
(Fig. 1B) (Buganim et al., 2012).
The subsequent transition from the initiation to matura-
tion phase is a major bottleneck for reprogramming. This has
been highlighted during human reprogramming as well,
through the systematic isolation of Tra-1–60 positive cells
(the equivalent of SSEA1 in mouse) which showed that most
of these cells could not progress to the maturation phase of
reprogramming (Tanabe et al., 2013).Intermediate events — maturation phase — second
wave
The maturation phase coincides with the second wave of
major transcriptional changes and is marked by the onset of
the first pluripotency-associated genes (Hansson et al.,
2012; Polo et al., 2012; Samavarchi-Tehrani et al., 2010).
This period is more protracted compared to the initiation
phase, and it can be further divided into different inter-
mediate states. During this phase, some pluripotency-
associated genes are gradually activated; some of the first
markers to be detected are Fbxo15, Sall4 and endogenous
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maturation phase, on the cusp of the stabilization stage,
it is possible to detect Sox2 or Dppa4, as cells can
self-renew independently of transgenes, (Buganim et al.,
2012; Golipour et al., 2012; Polo et al., 2012; Samavarchi-
Tehrani et al., 2010; Stadtfeld et al., 2008b). On this note,
the pluripotency-associated markers have played a pivotal
role from the start in the induced pluripotency field. In fact,
the first selection marker used as a predictive marker of
reprogramming by Takahashi and Yamanaka was Fbxo15.
Curiously, Fbox15 was a poor predictor of reprogramming
as it was also expressed in partially reprogrammed cells
(Takahashi and Yamanaka, 2006). Nevertheless, other
substitute markers such as Nanog and Oct4 were then used
in replacement (Maherali et al., 2007; Okita et al., 2007),
resulting in a more reliable assessment of achieving
reprogramming.
The functional relevance of early pluripotency markers,
or maturation genes, such as Nanog or endogenous-Oct4, is
reaffirmed by the virtue that some of these factors enhance
the reprogramming efficiency, and even substitute for some
of the Yamanaka factors. These candidates include Nr5a2,
Tbx3, Nanog or Esrrb (Buganim et al., 2012; Han et al., 2010;
Hanna et al., 2009; Heng et al., 2010). It is worthy to note
that while the maturation genes are good indicators of
reprogramming, their sole acquisition does not guarantee
complete reprogramming of cells (Buganim et al., 2012;
Golipour et al., 2012; Polo et al., 2012). This clearly
indicates that a necessary sequence of events must occur
late during reprogramming, with a hierarchical relationship
between those events.
As mentioned previously, through the use of clonal
approaches, single cell analysis and parallel multi-culture
techniques, multiple groups assessed the sequential events
occurring in the cells committed to reprogramming and were
able to properly investigate these late events. Two groups
utilized single cell transcriptomics of genes previously
identified in reprogramming populations (Buganim et al.,
2012; Polo et al., 2012). One group coupled this technology
with a clonal analysis (secondary cells originally seeded at
one cell per well after the initiation phase) and validated
the result by FISH (Buganim et al., 2012). The other groups
coupled this technology with systematic cell sorting at
different time points using previously described sequential
markers of cells undergoing reprogramming (Thy1−, SSEA1+,
Oct4+) (Polo et al., 2012). Although with some small dif-
ferences, both studies showed that cells acquire pluripotency
markers in a sequential way, with some being expressed
during the maturation phase (i.e. Nanog, Esrrb) and others
not expressed until the next late stabilization phase (i.e.
Sox2, Pecam), validating the hypothesis based on previous
transcriptomic studies or reporter genes (Samavarchi-Tehrani
et al., 2010; Stadtfeld et al., 2008b). These findings have
been further refined and confirmed through the use of a cell
surface marker, ICAM1, allowing for committed-cell popula-
tions to be enriched during the reprogramming process
(O'Malley et al., 2013).
An important feature of the late reprogramming event is
transgene silencing, or in other words, the ability of iPSC to
self-renew independently of the Yamanaka factors. Taking
advantage of a mouse secondary system in which the last
step does not occur in the presence of the transgenes,Golipour and collaborators studied the determinants of
transgene independency. Using clonal analysis and the
ability to survive transgene suppression, this group revealed
a signature associated with the competency to survive
transgene suppression and transit to the stabilization phase
(Golipour et al., 2012). The functional validity of this
stabilization competency signature was validated by a
siRNA screen performed on cells undergoing transgene
suppression, compared to the same siRNA screen repeated
in iPSC. While the universal pluripotency-associated factors
were found to be necessary for pluripotency in iPSCs, a
distinct regulatory network was found to be important for
survival upon transgene suppression. This demonstrated the
importance of events occurring after the acquisition of
pluripotency factors such as Oct4 or Nanog and how they
prepare the cells to self-renew in the absence of the
transgenes. Those events involved converting inactive DNA
regions coding for a subset of pluripotency associated factors
into poised regions, which correlated with the observation
that DNA methylation changes occur mostly at the end of the
reprogramming process (Polo et al., 2012).
The cellular and molecular events underpinning the
maturation phase are characterized by their hierarchical
and slow reactivation. However, how this happens remains
poorly understood. One hypothesis is that specific complexes
are required to activate each of the pluripotency genes,
therefore, acquisition of factors one after another is
necessary and explains the sequence of events. Potential
regulators have been recently identified as playing a dual
role by inhibition of the maturation phase program through
BMP signaling, which is present in the serum and feeders.
The recruitment of the polycomb group, the recruitment
of Utx, and the loss of Mbd3 subunit of the NuRD complex
have also been identified (Chen et al., 2013; Luo et al.,
2013; Mansour et al., 2012; Rais et al., 2013; Singhal et al.,
2010; Welstead et al., 2012). It remains to be shown how all
these findings are interconnected and what regulates the
redistribution of OKSM to those genes during the maturation
phase.
Finally, the importance of lifting the epigenetic barriers
during this period has recently been the center of a study
focused on B cell reprogramming, using mouse secondary B
cells as a model (Di Stefano et al., 2014). The authors found
out that overexpressing C/EBPα triggers the expression of
Tet2 in B cells, greatly improving reprogramming speed (Di
Stefano et al., 2014). Interestingly, in this other cell type,
upon overexpression of C/EBPα, two kinetics of pluripotency
markers were observed: a first early induced group of Oct4,
Lin28a and GDF3, and a later induced group with Nanog Sox2
and Esrrb. This highlights differential re-activation of
pluripotency genes, with some similarities in the sequence
(early Oct4, late Sox2) compared to MEF reprogramming.
Such a study has to be repeated with other cell types in order
to understand if there are multiple and different pathways
to reprogramming.Final events — stabilization phase
The stabilization phase encompasses the changes that occur
in iPSCs after they have acquired pluripotency (Ho et al.,
2011; Stadtfeld and Hochedlinger, 2010).
759Phases of reprogrammingOnce the cells undergoing reprogramming express the first
subset of pluripotency-associated genes (maturation-phase
genes) and remain poised for the second subset (stabilization-
phase genes), the cells are able to successfully transit to the
stabilization phase and acquire the full pluripotency signa-
ture, a pluripotent state that can be sustained independently
of ectopic reprogramming factor expression (Brambrink et
al., 2008; Maherali et al., 2007; Okita et al., 2007; Stadtfeld
et al., 2008b; Wernig et al., 2007). During this phase, the
iPSCs will be expanded and pluripotency will be assessed (i.e.
by blastocyst injection). Based on chimeric aggregation, cells
become pluripotent very shortly after suppression of trans-
gene expression. In human iPSCs, extensive passaging is also
necessary to adapt the cells to hESC growth conditions and
amplify them sufficiently before these can be applied in an
experimental setting. It also normalizes the minor differences
in expression profile that might exist between early hiPSCs
and hESCs (Chin et al., 2009).
While iPSCs are pluripotent at this point, numerous
epigenetic changes are occurring. An example in mouse is
telomere elongation back to an embryonic level (Marion et
al., 2009b; Stadtfeld et al., 2008b). The DNA is also subject
to important rearrangements, such as reactivation of the
inactive X chromosome in female mouse iPSCs (Stadtfeld
et al., 2008b). Understanding the mechanisms linking X
reactivation to the induction of pluripotency is particularly
relevant for human reprogramming, which often leads to
hiPCS with an inactive X chromosome, and disease modeling
(Papp and Plath, 2013). Other epigenetic rearrangements
can be assigned to the stabilization phase, such as the
resetting of epigenetic memory found in mouse and human
iPS cells derived from different somatic cell types. This
phenomenon of “epigenetic memory” has been shown to
bias iPS cells towards their donor somatic cell type of origin.
Interestingly, in accordance with the stabilization phase,
passaging the cells or treating them with 5-aza, a DNA
methylase inhibitor, helped to reset the epigenome to
prevent differentiation biases (Kim et al., 2011; Ohi et al.,
2011; Polo et al., 2010). Clearly, changes in DNA methylation
profiles that started in the late maturation phase continue
throughout the stabilization phase and are likely to be
responsible for the events associated with this phase. One
likely explanation is the reactivation of regulators of DNA
methylation, such as AID, TET family and DMNTs during the
late maturation/stabilization phase (Polo et al., 2012). AID
has been shown to be actively promoting this epigenetic
reset (Bhutani et al., 2010; Kumar et al., 2013). Further
study of the epigenetic rearrangements taking place late
during reprogramming is another area of great importance to
ensure the production of high quality iPSCs.Discussion
While the roadmap to reprogramming is now taking shape,
further refinement of this process is still needed. Indeed,
recent advances have shed light on different road blocks,
such as an improved OKSM stoichiometry (Carey et al., 2011)
and understanding that cells can become refractory to
reprogramming even by shutting down transgenic expression
systems (Polo et al., 2012). There is a molecular connectivity
or cascade of expression changes in specific genes during thereprogramming steps which have allowed the use of
different surface and genetic markers during the study of
the mechanism of reprogramming. As discussed, the initia-
tion stage is marked by Cdh1, alkaline phosphatase, and
SSEA1 followed by the maturation phase markers (e.g. Oct4,
Nanog) and the stabilization phase markers (e.g. Pecam1,
Sox2) which results in the production of bona fide iPSCs
(Buganim et al., 2012; Golipour et al., 2012; O'Malley et al.,
2013; Polo et al., 2012).
As the transcriptional signatures are now quite defined, it
seems that for a given starting cell type, the sequence of
events is highly conserved in nature and order. The last
question, the time latency issue, points out epigenetic
barriers such as, what makes a gene easier to reactivate
than others, especially among the pluripotency associated
genes? Bypassing the epigenetic barrier(s) is therefore a
major challenge and solving this issue will require an in
depth analysis of epigenetic regulatory events during
reprogramming, including 3D structure of the genome
studies, as performed recently with the Nanog promoter
(Apostolou et al., 2013). This should yield factor-based
or chemically-based reprogramming approaches matching
the speed and faithfulness of somatic-cell nuclear transfer
(SCNT) reprogramming. This is particularly relevant as human
ESCs derived by SCNT, thereby mimicking embryo-derived
ESCs, have just been successfully obtained (Tachibana et al.,
2013). Importantly, alternative cocktails of reprogramming
factors, for example by including Esrrb or knocking-down
Mbd3, have demonstrated that overcoming this barrier is
possible (Buganim et al., 2012; Luo et al., 2013; Rais et al.,
2013). It remains to be shown whether those alternative
or accelerated reprogramming strategies are changing the
sequence of events, and if they change the faithfulness of
reprogramming.
While most of the knowledge on the mechanisms of
reprogramming has been acquired using mouse models,
many of those mechanisms have also held true during human
reprogramming. This extraordinary rapid progress in our
understanding of nuclear reprogramming increases our hope
that in the foreseeable future, somatic cell reprogramming
will yield “perfect” iPSCs with high throughput and repro-
ducibility. Clinical applications and clinical trials using this
technology are already starting to appear and the develop-
ment of more reliable reprogramming protocols based on
mechanistic studies will help propel advancements in this
field.Acknowledgments
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